For more than a decade, the build-versus-buy debate has surfaced every time a new wave of technology reaches the life sciences industry. With the rise of generative AI, it has re-emerged with new intensity. Pharma and Medical Communications teams are now asking the same questions: 

• Should we build our own AI capability internally? 

• Should we rely on general-purpose LLMs? 

• Or should we partner with purpose-built platforms designed for the complexity of healthcare? 

The answer is becoming clearer as the sector undergoes its most significant structural shift in years. The current mergers signal a new competitive reality: data must sit at the centre of every decision, every campaign, and every dollar spent on scientific communication. Agencies and pharma companies alike can no longer win on craft alone. They must win on measurable impact. 

This forces a rethink of how AI is adopted. 

The Limitations of General-Purpose LLMs 

Generalised LLMs have been widely celebrated for their speed and efficiency. They can draft content, summarise information, and automate tasks that historically took teams hours or days. These efficiency gains matter, but they do not solve the core commercial problem facing pharma marketing today:
Pharma does not know whether its’ scientific messages actually land with healthcare professionals. 

An LLM cannot answer that. An LLM has to ethically contain sensitive information and cannot leak or be trained on the worldwide web. An LLM cannot measure real-world message resonance. An LLM cannot understand the nuance of language, behaviour, and unmet information needs without specialised, regulated, domain-specific architecture. And an LLM certainly cannot drive top-line revenue on its own. 

Efficiency lowers cost. It does not grow markets. 

Why “Build” Can Be a Costly Detour 

Many organisations attempt to build internal AI tools, believing it gives them control or cost savings. In reality, three barriers quickly surface: 

• Data scarcity and fragmentation
  Most internal teams do not have the in-house resource and skill to ingest unstructured, real-life HCP data in a compliant way. Without it, AI cannot generate meaningful insight. 

• Regulatory complexity
  Medical claims, adverse events, off-label risk, and therapeutic nuance make in-house development slow and expensive. 

• Lack of longitudinal intelligence
  Short-term experiments do not accumulate into a model capable of predicting behaviour or quantifying message resonance. Without this, AI becomes another dashboard, not a driver of commercial outcomes. 

Internal builds are rarely discontinued because they fail.
They are discontinued because they never become strategically valuable. 

The Case for Buying Purpose-Built AI: Where Talking Medicines Changes the Economics 

Talking Medicines DrugVoice exists for a single purpose:
To give Med Comms teams evidence about what matters to HCPs – from the real world, at scale. 

That requires: 

• Expertise in real-life HCP and patient data (ethically and compliantly collected alongside customers) 

• Domain-specific models built for the language of physicians 

• A proprietary HCP Message Resonance Score™ that quantifies message alignment 

• Predictive models  

These capabilities take years to build, validate, and govern.
They cannot be replicated quickly by generalised models.
 

This is why the value shifts from efficiency to top-line impact.
Customers using DrugVoice are improving message alignment, increasing HCP understanding, and strengthening prescribing intent. That is commercial growth, not operational optimisation. 

When the market competition is defined by who can prove the impact of every message, buying becomes the strategic choice.
 

A New Reality for Pharma and Agencies 

The IPG-Omnicom merger is the clearest sign yet that the market is entering a phase of exponential change. Scale alone is no longer enough.
Agencies must differentiate through: 

• Data-led strategy 

• Real-world evidence of message performance 

• Faster optimisation cycles 

• Predictive insight about audience behaviour 

Pharma has the same requirement internally.
Commercial teams must justify spend, accelerate time to value, and prove that their messages are understood consistently by the right prescribers. 

In this environment, purpose-built platforms like Talking Medicines DrugVoice are the new infrastructure for competitive advantage. 

Conclusion 

The build-versus-buy debate is shifting from a question of cost to a question of strategic necessity. General-purpose LLMs deliver efficiency. Purpose-built solutions deliver revenue. 

The organisations that succeed in the next decade will be those that align with specialised AI – that includes Data Science, ML and Natural Language Processing – designed for the complexity, regulation, and nuance of healthcare, and that use real-world HCP voice to guide every communication decision. 

The merger of two of the world’s largest agency groups marks the start of this new era.
The winners will be the companies who treat data not as an add-on, but as the foundation of how they communicate, differentiate, and grow.